

Jack J Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7023665/publications.pdf>

Version: 2024-02-01

32
papers

1,037
citations

430442

18
h-index

500791

28
g-index

32
all docs

32
docs citations

32
times ranked

1414
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's Disease. <i>Clinical Therapeutics</i> , 2007, 29, 1825-1849.	1.1	181
2	Tetrabenazine for the Treatment of Hyperkinetic Movement Disorders: A Review of the Literature. <i>Clinical Therapeutics</i> , 2012, 34, 1487-1504.	1.1	143
3	Anxiety in Parkinson's disease: identification and management. <i>Therapeutic Advances in Neurological Disorders</i> , 2014, 7, 52-59.	1.5	106
4	Pharmacotherapy for Parkinson's Disease. <i>Pharmacotherapy</i> , 2007, 27, 161S-173S.	1.2	80
5	Transdermal Rotigotine: A Clinically Innovative Dopamine Receptor Agonist for the Management of Parkinson's Disease. <i>Pharmacotherapy</i> , 2009, 29, 1452-1467.	1.2	53
6	Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 915-928.	0.5	50
7	A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease. <i>Clinical Therapeutics</i> , 2005, 27, 1710-1724.	1.1	40
8	Abo, Inco, Ona, and Rima Botulinum Toxins in Clinical Therapy: A Primer. <i>Pharmacotherapy</i> , 2013, 33, 304-318.	1.2	40
9	Essential Tremor: Diagnosis and Treatment. <i>Pharmacotherapy</i> , 2003, 23, 1105-1122.	1.2	39
10	Effect of Exercise on Motor and Nonmotor Symptoms of Parkinson's Disease. <i>Parkinson's Disease</i> , 2015, 2015, 1-5.	0.6	39
11	Depression in Parkinson's Disease: Identification and Management. <i>Pharmacotherapy</i> , 2013, 33, 972-983.	1.2	35
12	Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry. <i>Journal of the Neurological Sciences</i> , 2017, 376, 84-90.	0.3	30
13	Treatment of psychotic symptoms in patients with Parkinson disease. <i>Mental Health Clinician</i> , 2017, 7, 262-270.	0.5	28
14	The Monoamine Oxidase Type B Inhibitor Rasagiline in the Treatment of Parkinson Disease: Is Tyramine a Challenge?. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 620-628.	1.0	26
15	Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials. <i>Annals of Pharmacotherapy</i> , 2018, 52, 1182-1194.	0.9	22
16	OnabotulinumtoxinA and AbobotulinumtoxinA Dose Conversion: A Systematic Literature Review. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 109-115.	0.8	21
17	Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type B inhibitor: A Cross-sectional, Cohort Study. <i>Pharmacotherapy</i> , 2015, 35, 681-686.	1.2	19
18	RimabotulinumtoxinB in sialorrhea: systematic review of clinical trials. <i>Journal of Clinical Movement Disorders</i> , 2017, 4, 9.	2.2	19

#	ARTICLE	IF	CITATIONS
19	Pharmacologic Safety Concerns in Parkinson's Disease: Facts and Insights. <i>International Journal of Neuroscience</i> , 2011, 121, 45-52.	0.8	18
20	Systematic Literature Review of Quetiapine for the Treatment of Psychosis in Patients With Parkinsonism. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2019, 31, 188-195.	0.9	13
21	Community and Long-Term Care Management of Parkinson's Disease in the Elderly. <i>Drugs and Aging</i> , 2007, 24, 663-680.	1.3	9
22	Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects. <i>Drugs in R and D</i> , 2018, 18, 77-86.	1.1	7
23	Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Blepharospasm and Hemifacial Spasm. <i>Tremor and Other Hyperkinetic Movements</i> , 2015, 5, 338.	1.1	6
24	NonParkinsonism Movement Disorders in the Elderly. <i>The Consultant Pharmacist</i> , 2006, 21, 58-71.	0.4	5
25	GagnÃ©'s 9 Events of Instruction With Active Learning: Teaching Student Pharmacists How to Measure Blood Pressure. <i>Journal of Pharmacy Practice</i> , 2021, 34, 407-416.	0.5	3
26	Parkinson disease: A summary of recent evidence-based medicine reviews. <i>Mental Health Clinician</i> , 2012, 2, 25-31.	0.5	3
27	Implications for managed care for improving outcomes in Parkinson's disease: balancing aggressive treatment with appropriate care. <i>American Journal of Managed Care</i> , 2011, 17 Suppl 12, S322-7.	0.8	1
28	Pharmacotherapeutic management of pseudobulbar affect. <i>American Journal of Managed Care</i> , 2017, 23, S345-S350.	0.8	1
29	Cost Analysis of Pharmacy-Based Aminoglycoside Regimens: Once-Daily vs. Multiple Daily Dosing. <i>Hospital Pharmacy</i> , 2000, 35, 950-954.	0.4	0
30	The white coat. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, 611-611.	0.5	0
31	Movie Review: Requiem. <i>Mental Health Clinician</i> , 2013, 3, 273-275.	0.5	0
32	Reply to letter. <i>Mental Health Clinician</i> , 2018, 8, 200-201.	0.5	0